drugset / Trial / NCT01934829

Urea Cream Treatment Sorafenib-Associated HSFR in HCC

NCT01934829

Phase 2 Completed 871 enrolled Chinese Anti-Cancer Association
RandomizedParallel-groupOpen-labelPrevention

Summary

Although sorafenib is effective and safe in patients with advanced hepatocellular carcinoma (HCC), it increases dermatologic toxicities, including hand-foot skin reaction (HFSR), which may have a negative impact on patient quality of life (QoL). Urea-based creams may have a prophylactic effect on sorafenib-induced HFSR in HCC patients.

Timeline

Start
2009-07
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject urea Unknown 10 %